We are studying biological and therapeutic aspects of treatment resistant and metastatic cancer. Our goal is to contribute to a better understanding of the biological mechanisms involved in these procesess. We aim to use such information to identify novel therapeutic target or biomarkers to guid treatment decisions.

In our research we use:

1) preclinical model systems (in vitro, ex vivo, in vivo) to study molecular determinants and test novel therapies.

2) patient material from clinical intervention studies or prospectively collected biobanks to unravel novel targets and biomarkers.

The research group has three associated project groups:

• Urological Molecular Biology PI: Kristin A. Tasken
• Tumor-stroma interactions in metastasis and therapy PI: Lina Prasmickaite
• Molecular precision medicine in breast cancer PI: Mads H. Haugen

The group is partner in the National Network for Breast Cancer Research. We were also, together with clinical collaborators, responsible for the MetAction clinical study – the first Norwegian clinical trial in precision cancer medicine where targeted treatment was based on identification of actionable targets in metastatic biopsies.

Department of Tumor Biology, Institute for Cancer Research
The Norwegian Radium Hospital, Montebello, Box 4953 Nydalen, 0424 Oslo, Norway
Phone: +47 22 78 18 79(Mælandsmo) Fax: +47 22 78 17 95
Email: g.m.malandsmo@ous-research.no